Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611670 | 0.85 | FDPS (0.38) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL1748495 | 0.83 | FDPS (0.37) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL2507997 | 0.81 | FDPS (0.35) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL2120550 | 0.78 | FDPS (0.45) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL28340215 | 0.77 | FDPS (0.44) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL2776765 | 0.75 | PIK3CA (0.39) | HDAC6ALDH1A1CYP1A2PIK3CB | |
| Tetrahydrofuran SCHEMBL28855131 | 0.71 | FDPS (0.35) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL27734755 | 0.70 | FDPS (0.40) | FDPSMEN1KMT2AMKNK2HDAC1 | |
| SCHEMBL28444794 | 0.70 | FDPS (0.35) | FDPSMKNK2HDAC1HDAC6LTA4H | |
| SCHEMBL28271008 | 0.70 | FDPS (0.35) | FDPSMKNK2HDAC1HDAC6LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113832110-A | Induced pluripotent stem cell carrying GCH1 gene mutation and preparation method for differentiating induced pluripotent stem cell into neural precursor cell | 珠海乐维再生医学科技有限公司 | 2021-12-24 | — | — | CN | claimed |
| CN-106659765-A | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | 德玛医药 | 2017-05-10 | — | — | CN | claimed |
| CN-113832110-A | Induced pluripotent stem cell carrying GCH1 gene mutation and preparation method for differentiating induced pluripotent stem cell into neural precursor cell | 珠海乐维再生医学科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-109311843-B | Azabenzimidazole derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-108349946-B | Quinoxaline and pyridopyrazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20200079763-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-12 | — | — | US | disclosed |
| CN-110461827-A | Quinoxaline and pyrido-pyrazine derivatives as PI3K- beta inhibitor | JANSSEN PHARMACEUTICA NV | 2019-11-15 | — | — | CN | disclosed |
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| CN-109311843-A | Azabenzimidazoles derivative as PI3K beta inhibitor | 詹森药业有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311875-A | Two ring pyridines, two ring pyrazines and bicyclic pyrimidine derivatives as PI3K beta inhibitor | 詹森药业有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-108349946-A | Quinoxaline and pyrido-pyrazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-106659765-A | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | 德玛医药 | 2017-05-10 | — | — | CN | disclosed |
| CN-103003279-B | Purine compounds selective for PI3K P110 and methods of use thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-23 | — | — | CN | disclosed |
| CN-102459272-B | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH INC | 2014-08-06 | — | — | CN | disclosed |
| CN-102105474-B | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2014-01-08 | — | — | CN | disclosed |
| CN-103003279-A | Purine compounds selective for PI3K P110 delta and methods of use thereof | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
| CN-102459272-A | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | GENENTECH INC | 2012-05-16 | — | — | CN | disclosed |
| CN-102245607-A | Morpholinopurine derivative | DAIICHI SANKYO CO LTD | 2011-11-16 | — | — | CN | disclosed |
| CN-102105474-A | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CD, PIK3CB, PIK3CA | FDPS 936/4885MEN1 2562/4885KMT2A 1476/4885 |
| US-20200079763-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS | PIK3CB, PIK3CA, PIK3R5 | FDPS 713/4885MEN1 2911/4885KMT2A 2159/4885 |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | FDPS 352/4885MEN1 2870/4885KMT2A 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.